Has Michael Stubblefield, MD received payments from drug or device companies?

Yes. Drug and device makers reported $52,733 in general payments to Michael Stubblefield, MD across 61 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Stubblefield, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Stubblefield, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Stubblefield, MD

Physical Medicine & Rehabilitation · New York, NYNPI 1396716338

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $42,450 of the $52,733 with a category attached, or 80.5%. Tactile Systems Technology Inc accounts for 98.2% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $38,479, more than ten times the $326 reported in 2019. Among physical medicine & rehabilitation clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$52,733in general payments, 2019–2025

Across 61 payments — averaging $864.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Tactile Systems Technology Inc$52K
AbbVie$634
Merz Pharmaceuticals, LLC$39
Merz North America, Inc.$35
Azurity Pharmaceuticals, Inc.$31
Pacira Therapeutics, Inc.$27
plus $194 from 12 others

What the payments were for

Consulting fees$3,8757%
Speaking & faculty fees$42,45081%
Travel & lodging$4,6109%
Food & beverage$1,7983%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Tactile Systems Technology Inc	31	$51,773
AbbVie(2 entities)	9	$634
Merz Pharmaceuticals, LLC	2	$39
Merz North America, Inc.	2	$35
Azurity Pharmaceuticals, Inc.	2	$31
Pacira Therapeutics, Inc.	2	$27
Collegium Pharmaceutical, Inc.	2	$25
Abbott	1	$20
Axsome Therapeutics, Inc.	1	$18
Coloplast	1	$17
Otsuka America Pharmaceutical, Inc.	1	$16
Lundbeck LLC	1	$16
Pfizer	1	$15
Ultragenyx Pharmaceutical Inc.	1	$14
Biogen	1	$14
Teva Pharmaceuticals USA, Inc.	1	$14
Sanofi-aventis U.S. LLC	1	$13
Avanir Pharmaceuticals, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Flexitouch Plus$44,464
Nimbl$38,219
ENTRE$8,865
FLEXITOUCH$6,940
ACTITOUCH$6,940
Entre Plus$4,320
BOTOX$522

How this compares

$52,733 in reported general payments places this provider in the 95th percentile of 872 physical medicine & rehabilitation providers in New York.

See all physical medicine & rehabilitation providers in New York →

Medicare billing

Part B allowed, 2024

$101,092

Medicare patients

Services billed

8,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OxycontinOxycodone Hcl	39	$47,801
Pregabalin	130	$2,217
Morphine Sulfate ErMorphine Sulfate	27	$1,513
Celecoxib	42	$1,265
Duloxetine Hcl	69	$1,126
Oxycodone Hcl	51	$966
Morphine Sulfate	12	$252
Gabapentin	22	$157
Hydromorphone Hcl	14	$112
Sumatriptan Succinate	22	$103
Cyclobenzaprine Hcl	13	$21

Paid to pharmacies, not to this prescriber.

Other physical medicine & rehabilitation in New York

Heidi FuscoNew York$153K
Michael OdellNew York$67K
Craig AntellNew York$65K
Heakyung KimNew York$53K
Russell SilverNew York$34K
Julia IafrateNew York$32K
Neil JaseyNew York$29K
Christian CustodioNew York$19K
Karan JoharNew York$14K
Samantha ErosaNew York$14K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →